Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of SFRT + LDRT with QL1706 and chemotherapy in immunotherapy-resistant advanced driver-negative NSCLC
ChiCTR2600135490Phase 2Not yet recruiting
- Sponsor
- Union Hospital
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in non-small cell lung cancer (NSCLC), sponsored by Union Hospital. Primary endpoints: Progression-free survival and Adverse event rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600135490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135490.